NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1991.85 23.40 (1.19%)

33.39% Gain from 52W Low

559.7K NSE+BSE Volume

NSE 17 Mar, 2025 3:31 PM (IST)

90,936.1

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Lupin gets US FDA tentative approval for Amifampridine tablets, with a market size of $306 million See details

Lupin Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news and updates on Lupin Ltd. from all sources in a single place.

Load latest

Is Lupin Ltd. worth buying?

907 Votes:

Buy 72.66%

Sell 17.64%

Hold 9.7%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf